FTC Commissioner Slams Authorized Generics

Law360, New York (July 20, 2006, 12:00 AM EDT) -- Patent litigation that ends in authorized generic agreements poses a significant threat to competition in the pharmaceutical industry, said Federal Trade Commissioner Jon Leibowitz at a Thursday hearing before the U.S. Senate Special Commission on Aging.

Leibowitz blasted the agreements, saying that “although both the brand company and the generic company are better off financially, these settlements restrict competition at the expense of consumers, whose access to lower-priced generic drugs may be deferred for years.”

The Commissioner said that although the FTC has been successful in...
To view the full article, register now.